#antibodies

The findings provide a basis for future studies of the immune system’s role in longevity.

90% of people who received an injection of lenacapavir plus two broadly neutralizing antibodies maintained viral suppression for six months.

NIAID-supported research sheds light on why healthy people of the same age respond differently to vaccines.

A single vaccine dose delivered to nose aims to protect children and adults against COVID.

The experimental antibody, dubbed N6LS, demonstrated strong antiviral activity in a Phase II study.

Broadly neutralizing antibodies (bnAbs) can delay HIV rebound and even lead to long-term remission.

Two broadly neutralizing antibodies delayed HIV rebound in people who started antiretroviral therapy early.

She has not experienced viral rebound and tests negative for HIV antibodies.

A combination of two antibodies, dubbed 3BNC117 and 10-1074, maintained viral suppression for a year in two people.

HIV mutates rapidly, enabling the virus to evade the common, narrowly targeted antibodies produced by most people with HIV.

An amfAR grant will help find out. Plus, the AIDS research group also awards three new Mathilde Krim HIV fellowships.

Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.

The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.

The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.

Different mechanisms suppressed the virus in each person.

The findings could have implications for vaccines against other rapidly evolving pathogens, such as influenza virus or SARS-CoV-2.